Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Aims
To investigate the effects of a single dose of 1.2 mg liraglutide, a once‐daily glucagon‐like peptide‐1 (GLP‐1) receptor agonist, on key renal variables in patients with type 2 diabetes.
Methods
The study was a placebo‐controlled, double‐blind, crossover trial in 11 male patients with type 2 diabetes. Measurements included 51Cr‐EDTA plasma clearance estimated glomerular filtration rate (GFR) and MRI‐based renal blood flow (RBF), tissue perfusion and oxygenation.
Results
Liraglutide had no effect on GFR [95% confidence interval (CI) −6.8 to 3.6 ml/min/1.73 m2] or on RBF (95% CI −39 to 30 ml/min) and did not change local renal blood perfusion or oxygenation. The fractional excretion of lithium increased by 14% (p = 0.01) and sodium clearance tended to increase (p = 0.06). Liraglutide increased diastolic and systolic blood pressure (3 and 6 mm Hg) and heart rate (2 beats per min; all p < 0.05). Angiotensin II (ANG II) concentration decreased by 21% (p = 0.02), but there were no effects on other renin‐angiotensin system components, atrial natriuretic peptides (ANPs), methanephrines or excretion of catecholamines.
Conclusions
Short‐term liraglutide treatment did not affect renal haemodynamics but decreased the proximal tubular sodium reabsorption. Blood pressure increased with short‐term as opposed to long‐term treatment. Catecholamine levels were unchanged and the results did not support a GLP‐1–ANP axis. ANG II levels decreased, which may contribute to renal protection by GLP‐1 receptor agonists.